Dr. Christopher D. Ferris, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 378
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Johns Hopkins University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NC license 200400857
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carolinas Medical Center/behav Health Charlotte, NC
- Atrium Health Pineville Charlotte, NC
- Atrium Health Union Monroe, NC
Medical groups
- Tryon Medical PArtners, PLLC (141 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 378
- Services billed
- 1,178
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 207 | 129 |
| Established patient office or other outpatient visit, 30-39 minutes | 172 | 138 |
| New patient office or other outpatient visit, 45-59 minutes | 116 | 116 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 62 | 41 |
| Blood test, comprehensive group of blood chemicals | 55 | 36 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 29 |
| Imaging of digestive tract done from the inside of the digestive tract | 29 | 29 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Charlotte, NC | 216 |
| Omeprazole Other prescribers in Charlotte, NC | 111 |
| Famotidine Other prescribers in Charlotte, NC | 75 |
| Doxycycline Hyclate Other prescribers in Charlotte, NC | 49 |
| Budesonide Dr (budesonide) Other prescribers in Charlotte, NC | 45 |
| Linzess (linaclotide) Other prescribers in Charlotte, NC | 44 |
| Xifaxan (rifaximin) Other prescribers in Charlotte, NC | 33 |
| Budesonide Ec (budesonide) Other prescribers in Charlotte, NC | 28 |
| Sucralfate Other prescribers in Charlotte, NC | 26 |
| Colestipol Hcl Other prescribers in Charlotte, NC | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 113 payments worth $2,692 in total to this clinician.
| Janssen Biotech, Inc. | $360 |
|---|---|
| Pfizer Inc. | $325 |
| AbbVie Inc. | $292 |
| Genzyme Corporation | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | $243 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221 |
| Aimmune Therapeutics, Inc. | $195 |
| Phathom Pharmaceuticals, Inc. | $147 |
| Food and Beverage | $2,692 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $183,833 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combinat…
Janssen Research & Development, LLC - A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combinat…
Janssen Research & Development, LLC - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)
Janssen Research & Development, LLC - A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Sanofi US Services Inc. · Active, not recruiting · NCT05731128 - Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04530123
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.